PD-L1 IHC 22C3 pharmDx
Agilent Technologies, Inc. · Decision date Sep 21, 2026
What did the FDA decide?
The FDA recorded decision OK30 on 2026-09-21 for PMA supplement P150013/S034, submitted by Agilent Technologies, Inc. as a 30-Day Notice under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The supplement concerns PD-L1 IHC 22C3 pharmDx, an immunohistochemistry assay in the Pathology specialty under product code PLS. The recorded statement describes approval for a supplier's change to the manufacturing site for a device component.
This action covers only that supplier and manufacturing-site change within the existing P150013 approval; it is not a new approval of the assay as a whole. The source record does not identify the affected component, the supplier, the specific sites, or any supporting documents, and it gives no clinical or performance data. Whether the change affects labeling, analytical validation, or intended use cannot be determined from the available fields.
FDA approval order statement
approval for a supplier's change to the manufacturing sight for a device component
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Sep 21, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150013/S034
- Regulatory pathway
- PMA supplement
- Applicant
- Agilent Technologies, Inc.
- Product code
- PLS
- Decision code
- OK30
- Decision date
- Sep 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry assay, antibody, programmed death-ligand 1.
- Applicant
- Agilent Technologies, Inc.
- Product code
- PLS
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P150013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150013 · Original PMA
PD-L1 IHC 22C3 PHARMDX
P150013/S034 received
Application receipt date recorded by FDA.
P150013/S035 · Related supplement
PD-L1 IHC 22C3 pharmDx
P150013/S034 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P150013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PD-L1 IHC 22C3 PHARMDXP150013 | Agilent Technologies, Inc. | PMA approval | Oct 2, 2015 | FDA |
PD-L1 IHC 22C3 pharmDxP150013/S035 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5301 Stevens Creek Blvd., Santa Clara, CA, 95051
Sources and methodology
- Original FDA record: P150013/S034
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
